• In this report, we summarize the case of a patient with MM status post autologous HSCT and chronic kidney disease who experienced worsening hypertension along with a substantial increase in proteinuria shortly after the initiation of carfilzomib for the treatment of refractory disease. (biomedcentral.com)
  • Positive data from the TOURMALINE-MM3 trial, the first and only Phase 3 placebo-controlled study evaluating a proteasome inhibitor in this setting, showed that using NINLARO as a post-autologous stem cell transplant maintenance treatment improved progression-free survival over the control arm, highlighting NINLARO's potential use as a maintenance therapy in a patient population where there are currently limited options. (covaipost.com)
  • Our study sought to develop a reliable signature incorporating T cell marker genes (TMGs) for predicting the prognosis and therapy responsiveness of head and neck squamous cell carcinoma (HNSCC) patients. (bvsalud.org)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • CheckMate -67T is a Phase 3 randomized, open-label trial evaluating subcutaneous administration of Opdivo co-formulated with Halozyme's proprietary recombinant human hyaluronidase, rHuPH20, or subcutaneous nivolumab (nivolumab and hyaluronidase) compared to intravenous (IV) Opdivo , in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy. (businesswire.com)
  • Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than 431,000 new cases and 179,000 deaths worldwide each year. (businesswire.com)
  • Clear cell renal carcinoma (ccRCC) is the most common form of RCC, affecting about 7 out of 10 people with RCC. (businesswire.com)
  • OPDIVO ® (nivolumab), in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC). (opdivohcp.com)
  • OPDIVO is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy. (opdivohcp.com)
  • OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (opdivohcp.com)
  • OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC). (opdivohcp.com)
  • Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. (biomedfrontiers.org)
  • The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers, but its role in primary and metastatic non-small cell lung carcinoma (NSCLC) remains to be determined. (biomedfrontiers.org)
  • The two largest subtypes of lung cancer are adenocarcinoma and squamous cell carcinoma, which together account for about 80% of non-small cell carcinomas (NSCLS). (biomedfrontiers.org)
  • Opdivo and Opdivo -based combinations are important treatment options with established benefit across many cancer types, including melanoma, renal cell carcinoma, non-small cell lung cancer, mesothelioma, head and neck cancer, and bladder cancer, as well as esophageal, gastric, and gastroesophageal junction cancers. (bms.com)
  • Even with notable progress in the treatment of metastatic renal cell carcinoma, there are still limited treatment options available for patients with localized disease," said Dana Walker, M.D., M.S.C.E., vice president, development program lead, genitourinary cancers, Bristol Myers Squibb. (wapakdailynews.com)
  • CheckMate -914 is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating Opdivo in combination with Yervoy compared to placebo (Part A), and Opdivo alone compared to placebo (Part B), in patients with localized renal cell carcinoma (RCC) who have undergone surgery to remove part or all of a kidney and who are at moderate to high risk of relapse. (wapakdailynews.com)
  • After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. (biomedcentral.com)
  • Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. (biomedcentral.com)
  • Our finding revealed that this TMG signature independently functioned as a prognostic marker and guided individualized immunotherapy and chemotherapy selection for patients with HNSCC. (bvsalud.org)
  • and chemotherapy and radiotherapy can have a negative effect on normal cells. (wikipedia.org)
  • Additionally, the positive data from the ECHELON-2 trial demonstrated that in patients with previously untreated CD30-positive peripheral T-cell lymphoma, ADCETRIS in combination with chemotherapy was superior to the control arm for progression-free survival and overall survival, representing an important milestone for ADCETRIS as a potential therapy in this setting where standard of care has not changed in several decades. (covaipost.com)
  • Case presentation Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. (bmj.com)
  • MCL can be both indolent or aggressive, in either case it responds poorly to chemotherapy and consequently the aggressive form has a dismal prognosis assessed by incorporating Ki-67 proliferation index and Mantle Cell International Prognostic Index scores. (bmj.com)
  • Allo-HSCT includes administration of a chemotherapy-based conditioning regimen (myelo-ablative or non-myelo-ablative), followed by infusion of alloreactive haematopoietic stem cells, with the aim of inducing an active immunological anti-tumoral effect. (biomedcentral.com)
  • I am scheduled to undergo stem cell transplantation and chemotherapy in the next month due to recurrence of lymphoma in the lymph nodes surrounding my spleen. (pocketdentistry.com)
  • Explained to patient the oral complications of HSCT, chemotherapy, and radiation. (pocketdentistry.com)
  • OPDIVO ® (nivolumab), in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). (opdivohcp.com)
  • OPDIVO, in combination with YERVOY and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. (opdivohcp.com)
  • OPDIVO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. (opdivohcp.com)
  • Current therapies for NSCLC including chemotherapy regimens and drugs that target molecular changes in cancer cells have considerable downsides. (biomedfrontiers.org)
  • Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC), regardless of PD-L1 expression levels. (advfn.com)
  • We are ecstatic to see Opdivo plus Yervoy continue to demonstrate almost double the overall survival rates as chemotherapy after six years of follow-up - the longest-ever for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer. (advfn.com)
  • Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)
  • CheckMate -77T is a Phase 3 randomized, double-blind, placebo-controlled, multi-center trial evaluating neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo versus neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo in 452 patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). (santaclara.com)
  • Interestingly, chemotherapy, including hydroxyurea, has been associated with acute leukemia in JAK2 V617F-negative stem cells in some PV patients. (basicmedicalkey.com)
  • The enrichment analyses of both pathways and functions showed that high- and low-risk patients had functionally related distinctions. (bvsalud.org)
  • Furthermore, analysis of the immunological landscape confirmed that the low-risk patients had a larger percentage of infiltrating immune cells as well as a higher incidence rate of immune-related events. (bvsalud.org)
  • Because impairment of kidney function in patients with multiple myeloma (MM) can be caused by a variety of conditions, ascertaining the etiology of kidney dysfunction in patients with MM represents a challenging task for the practicing nephrologist. (biomedcentral.com)
  • With the presentation of data from two Phase 3 clinical trials as well as our pipeline, Takeda continues to grow the body of evidence for new therapeutic options that improve the way in which we treat blood cancer patients," said Christophe Bianchi, M.D., President, Takeda Global Oncology Business Unit. (covaipost.com)
  • At this year's ASH meeting, data from the Phase 3 TOURMALINE-MM3 trial, evaluating the effect of NINLARO (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT), will be presented for the first time during an oral session on Sunday, December 2 at 7:30 a.m. (covaipost.com)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? (biomedcentral.com)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • The American Society of Parenteral and Enteral Nutrition (ASPEN) and the French-speaking society of clinical nutrition and metabolism (SFNEP) recommend nutritional support during haematopoietic transplantation for patients who are malnourished or have decreased intake or decreased intestinal absorption over a prolonged period (grade B) [ 11 , 12 ]. (biomedcentral.com)
  • For practical and historical reasons, parenteral nutrition (PN) is often the first option chosen for patients undergoing an allo-HSCT [ 13 ]. (biomedcentral.com)
  • Indeed, allo-HSCT patients all have a central-venous access that facilitates PN administration. (biomedcentral.com)
  • Lung transplantation is a life-saving surgical replacement of diseased lungs in patients with end-stage respiratory malfunctions. (biomedcentral.com)
  • Lung transplantation is a life-saving surgical procedure for patients with end-stage lung diseases. (biomedcentral.com)
  • Seven eighty six patients undergoing allogeneic (n=550) or autologous (n=236) BMT were evaluated by physical examination, history, rest and exercise ECG, chest x-ray, two-dimensional echocardiography, and radionuclide ventriculography (RNV) before BMT, and monitored for 5 months thereafter. (slideshare.net)
  • Thirty-eight patients (4.83%) had pathologic findings before transplantation. (slideshare.net)
  • We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. (meetingonthemed.com)
  • OPDIVO, in combination with YERVOY ® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. (opdivohcp.com)
  • The final sample consisted of 35 records patients aged between 2 and 18 years old who underwent HSCT from February 2008 to December 2015 and who presented the data necessary for the study. (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • The long-term efficacy seen with the dual immunotherapy regimen in CheckMate -227 reinforce the importance of nivolumab plus ipilimumab to transform outcomes for appropriate patients with metastatic non-small cell lung cancer. (advfn.com)
  • Patients with CLL have a higher-than-normal white blood cell count, which is determined by complete blood count (CBC). (medscape.com)
  • The cells of origin in most patients with CLL are clonal B cells arrested in the B-cell differentiation pathway, intermediate between pre-B cells and mature B cells. (medscape.com)
  • Food and Drug Administration approved brigatinib (ALUNBRIG, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (blogspot.com)
  • Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)
  • Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. (blogspot.com)
  • Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). (santaclara.com)
  • We've seen tremendous scientific advancements in the treatment of non-metastatic non-small cell lung cancer in recent years, and remain committed to researching new solutions that may help even more patients achieve better long-term outcomes," said Abderrahim Oukessou, M.D., vice president, thoracic cancers global program lead, Bristol Myers Squibb. (santaclara.com)
  • In approximately 15% of patients, however, myelofibrosis is accompanied by significant extramedullary hematopoiesis, hepatosplenomegaly, and transfusion-dependent anemia, which are manifestations of stem cell failure. (basicmedicalkey.com)
  • Patients with massive splenomegaly are particularly prone to thrombotic events because the associated increase in plasma volume masks the true extent of the red cell mass elevation measured by the hematocrit or hemoglobin level. (basicmedicalkey.com)
  • The use of salicylates as a tonic against thrombosis in PV patients is not only potentially harmful if the red cell mass is not controlled by phlebotomy, but is also an unproven remedy. (basicmedicalkey.com)
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)
  • Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. (u-tokyo-hemat.com)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. (biomedcentral.com)
  • BALB/c → C57BL/6 allografts were reconstituted with iPSC-derived MSCs (2 million/transplant/at d0), and allografts were examined for regulatory T cells (Tregs), oxygenation, microvascular blood flow, airway epithelium, and collagen deposition during rejection. (biomedcentral.com)
  • Since the first successful organ transplant in 1954, advancements in medical technology, immunology, and pharmacology have increased the success rate of solid organ transplantation. (pocketdentistry.com)
  • Data from the United Network of Organ Sharing ( UNOS ) and the Organ Procurement and Transplantation Network ( OPTN ) catalog over 175,000 transplants between the years 2000 and 2015 (Optn.transplant.hrsa.gov 2016 ). (pocketdentistry.com)
  • Transplant Cell Ther 2021. (harvard.edu)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Impairment of the ability to coordinate the movements required for normal ambulation (WALKING) which may result from impairments of motor function or sensory feedback. (lookformedical.com)
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)
  • Stem cell-based immunotherapy has been recognized as a crucial immunoregulatory regimen in various preclinical and clinical studies. (biomedcentral.com)
  • Cell-mediated immunotherapy is emerging as an alternative in single and combination therapies to rescue rejecting transplants. (biomedcentral.com)
  • Immunotherapy utilizing T cell immunity has become a new treatment to eliminate cancer cells. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
  • Independent origins of fetal liver haematopoietic stem and progenitor cells. (u-tokyo-hemat.com)
  • Cardiac complications have been described in HSCT with the majority of reported cardiac complications during HSCT attributed to the use of high-dose cyclophosphamide [30]. (slideshare.net)
  • Many of the clinical complications of PV relate directly to the increase in blood viscosity associated with red cell mass elevation and indirectly to the increased turnover of red cells, leukocytes, and platelets with the attendant increase in uric acid and cytokine production. (basicmedicalkey.com)
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
  • Two died while receiving high-dose systemic corticosteroids, methotrexate, and after recent exposure to anti-tumor necrosis factor-α biological DMARDs, and 2 during hematopoietic stem cell transplantation procedure. (cdc.gov)
  • T cells are among the most potent anti-tumor cells that are found in humans. (bvsalud.org)
  • A single cancer cell is invisible to the naked eye but can regrow into a new tumor, a process called recurrence. (wikipedia.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • BCMA, a member of the tumor necrosis factor (TNF) superfamily, is exclusively expressed in a subpopulation of B cells, normal plasma cells, and malignant plasma cells. (biomedcentral.com)
  • Affini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. (meetingonthemed.com)
  • Boehringer Ingelheim's collaboration with nanoPET Pharma has the potential to eliminate the hurdle that many cancer biologics face: getting access to targets inside tumor cells," said Norbert Kraut, Ph.D., Global Head of Cancer Research, Boehringer Ingelheim. (blogspot.com)
  • ICD's MacroDel technology exploits transporter proteins in the cell membrane to deliver such drug candidates inside tumor cells. (blogspot.com)
  • After binding with the biologic, the resulting compound selectively interacts with transporter proteins known to be highly expressed on tumor cell wall membranes. (blogspot.com)
  • Conclusions This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf "universal" CAR T cell therapy. (bmj.com)
  • Myeloablative allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure usually accompanied by multifactorial malnutrition, prompting the recommendation of systematic artificial nutritional support. (biomedcentral.com)
  • Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is a major procedure, and is usually conducted to consolidate remission of haematological malignancies. (biomedcentral.com)
  • CCDC88C-FLT3 gene fusion in CD34-positive haematopoietic stem and multilineage cells in myeloid/lymphoid neoplasm with eosinophilia. (u-tokyo-hemat.com)
  • The novel Cymerus™ manufacturing facilitates production of a virtually limitless supply of consistent human induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells, which could play a key role in selective immunosuppression and graft repair during rejection. (biomedcentral.com)
  • Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of transformed monoclonal plasma cells in the bone marrow (BM) [ 1 ]. (biomedcentral.com)
  • BCMA is not present in other hematological cells like hematopoietic stem cells or other tissues. (biomedcentral.com)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Taken together with the data from our CheckMate -816 trial - which led to Opdivo being the only anti-PD-1 with an approval in the neoadjuvant setting - today's results reinforce our leadership in resectable non-small cell lung cancer and add to our legacy of transformational science in thoracic cancers. (santaclara.com)
  • Examples of surgical procedures for cancer include mastectomy for breast cancer, prostatectomy for prostate cancer, and lung cancer surgery for non-small cell lung cancer. (wikipedia.org)
  • See selected safety profiles for other non-small cell lung cancer indications. (opdivohcp.com)
  • Moreover, shRNA-mediated knockdown of RHAMM reduced the migratory ability of two lung adenocarcinoma cell lines, H1975 and H3255. (biomedfrontiers.org)
  • To further confirm that RHAMM is upregulated in NSCLC, we looked at mRNA levels in 57 paired lung adenocarcinomas and 49 pair lung squamous cell carcinomas from The Cancer Genome Atlas (TCGA). (biomedfrontiers.org)
  • Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, representing up to 84% of diagnoses. (santaclara.com)
  • Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. (bmj.com)
  • Chronic Granulomatous Disease , autoimmune diseases Autoimmune diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. (lecturio.com)
  • AffyXell Therapeutics is a joint venture between Daewoong Pharmaceutical and Avacta Group, developing a novel cell and gene therapy to tackle diseases that come from the imbalance of immune system homeostasis. (meetingonthemed.com)
  • Agents that suppress immune function by one of several mechanisms of action. (lookformedical.com)
  • An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response. (lookformedical.com)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • EN and PN need to be prospectively compared in order to assess their impacts and to provide treatment guidelines. (biomedcentral.com)
  • We demonstrated that iPSC-derived MSC treatment leads to significant increases in hTSG-6 protein, followed by an upregulation of mouse Tregs and IL-5, IL-10, and IL-15 cytokines, which augments graft microvascular blood flow and oxygenation, and thereby maintained a healthy airway epithelium and prevented the subepithelial deposition of collagen at d90 post transplantation. (biomedcentral.com)
  • The immunomodulation function by MSC is further increased with the Affimer®, and the treatment developed by the AFX platform enhances restoring immunologic balance. (meetingonthemed.com)
  • This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
  • Several studies show that malnutrition is an independent negative prognostic factor for the survival of children and adults affected by malignant haematological disease and treated by allo-HSCT [ 5 - 8 ]. (biomedcentral.com)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • Peptic ulcer disease can also be due to Helicobacter pylori infection, the incidence of which is increased in PV, while the pruritus associated with this disorder may be a consequence of mast cell activation by JAK2 V617F. (basicmedicalkey.com)
  • Immunotolerance is a major immunological phase, which facilitates reparative microenvironment during transplantation, and plays a vital role to suppress alloimmune responses. (biomedcentral.com)
  • Peripheral smear from a patient with chronic lymphocytic leukemia, small lymphocytic variety. (medscape.com)
  • Sixty percent of cases express 1 or more T-cell antigens (CD3 + , CD43, or CD45RO). (medscape.com)
  • Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
  • IFN-γ release assays (IGRAs) are in vitro blood tests that measure T-cell release of IFN-γ after stimulation with antigens unique to Mycobacterium tuberculosis . (atsjournals.org)
  • Typical isoantigens are the BLOOD GROUP ANTIGENS. (lookformedical.com)
  • Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains. (lookformedical.com)
  • Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (lookformedical.com)
  • or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (lookformedical.com)
  • Renal pathology in TMA is characterized by thickened capillary walls, occlusion of vascular lumens, fibrin deposition and endothelial separation with expansion of subendothelial zone. (biomedcentral.com)
  • The spleen is highly vascular and acts as an important blood filter, cleansing the blood of pathogens and damaged erythrocytes. (lecturio.com)
  • Therefore, we propose that damage to and subsequent release of mtDNA elicits a protective signalling response that enhances nDNA repair in cells and tissues, suggesting that mtDNA is a genotoxic stress sentinel. (regenerativemedicine.net)
  • In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient. (biomedcentral.com)
  • There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • This meeting will feature in-person presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies. (meetingonthemed.com)
  • To characterize the clinical and epidemiological profile of children and adolescents submitted to HSCT at a referral service in the state of Rio Grande do Norte. (bvsalud.org)
  • In cultured primary fibroblasts and cancer cells, the chemotherapeutic drug doxorubicin causes mtDNA damage and release, which leads to cGAS STING dependent ISG activation. (regenerativemedicine.net)
  • Haplo-CAR T cells could effectively proliferate in vivo and had a clinically significant antitumor activity without serious side effects. (bmj.com)
  • In addition, we are committed to graft engineering and vaccine development to enhance the ability of transplantation to control blood diseases. (harvard.edu)
  • For this reason, the pathologist will examine the surgical specimen to determine if a margin of healthy tissue is present, thus decreasing the chance that microscopic cancer cells are left in the patient. (wikipedia.org)
  • Radiation therapy (also called radiotherapy, X-ray therapy, or irradiation) is the use of ionizing radiation to kill cancer cells and shrink tumors by damaging their DNA (the molecules inside cells that carry genetic information and pass it from one generation to the next), making it impossible for these cells to continue to grow and divide. (wikipedia.org)
  • Our differentiated cell therapy platform harnesses state-of-the-art engineering and synthetic biology capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. (meetingonthemed.com)
  • Engineered proteins and peptides offer great potential to block protein-protein interactions inside cancer cells, but their large size is generally assumed to prevent intracellular delivery. (blogspot.com)
  • The patient received multiple molecularly targeted therapies, including targeting BTK and BCL2, and haplo-identical CAR T (haplo-CAR T) cells from her daughter without previous allo-hematopoietic stem cell transplantation. (bmj.com)
  • In 2001, at age 21, the patient experienced an episode of severe pain and vomiting and was taken to the emergency room for a complete blood work up. (pocketdentistry.com)
  • A "normal" hematocrit or hemoglobin level in a PV patient with massive splenomegaly should be considered indicative of an elevated red cell mass until proven otherwise. (basicmedicalkey.com)
  • AffyXell's platform (also known as AFX) was created by converging two proprietary technologies of its parent companies - Daewoong's mesenchymal stem cell (MSC) and Avacta's Affimer® platform. (meetingonthemed.com)
  • Adaptive redox response of mesenchymal stromal cells to stimulation with lipopolysaccharide inflammagen: mechanisms of remodeling of tissue barriers in sepsis. (biomedfrontiers.org)
  • HSCT, there are still some factors that need to be metabolism disorders, among others. (bvsalud.org)